Observational study / 2017
An alkaline diet along with EGFR-TKI therapy was evaluated in 11 patients with EGFR mutation-positive NSCLC.
Eleven advanced or recurrent NSCLC patients with EGFR mutations who received EGFR-TKI therapy after being instructed to follow an alkaline diet were retrospectively evaluated. The median progression-free survival and overall survival were 19.5 (range = 3.1-33.8) and 28.5 (range = 15.4-46.6) months, respectively. The average dosage of EGFR-TKI was 56±22% of the standard dosage. Urine pH increased significantly after the alkaline diet from 6.00±0.38 to 6.95±0.55 (p < 0.05).
Shows an association, not proof of cause and effect.
- Study type
- Retrospective cohort study
- Who was studied
- 11 advanced or recurrent NSCLC patients with EGFR mutations
- What was measured
- Progression-free survival, overall survival, EGFR-TKI dosage, and urine pH
THE PAPER
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Hamaguchi R, Okamoto T, Sato M, Hasegawa M, Wada H. Anticancer Res, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.